Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2023 Nov;50(13):3982-3995.
doi: 10.1007/s00259-023-06330-0. Epub 2023 Jul 25.

Feasibility of [18F]fluoropivalate hybrid PET/MRI for imaging lower and higher grade glioma: a prospective first-in-patient pilot study

Affiliations
Comment

Feasibility of [18F]fluoropivalate hybrid PET/MRI for imaging lower and higher grade glioma: a prospective first-in-patient pilot study

Shahriar Islam et al. Eur J Nucl Med Mol Imaging. 2023 Nov.

Abstract

Purpose: MRI and PET are used in neuro-oncology for the detection and characterisation of lesions for malignancy to target surgical biopsy and to plan surgical resections or stereotactic radiosurgery. The critical role of short-chain fatty acids (SCFAs) in brain tumour biology has come to the forefront. The non-metabolised SCFA radiotracer, [18F]fluoropivalate (FPIA), shows low background signal in most tissues except eliminating organs and has appropriate human dosimetry. Tumour uptake of the radiotracer is, however, unknown. We investigated the uptake characteristics of FPIA in this pilot PET/MRI study.

Methods: Ten adult glioma subjects were identified based on radiological features using standard-of-care MRI prior to any surgical intervention, with subsequent histopathological confirmation of glioma subtype and grade (lower-grade - LGG - and higher-grade - HGG - patients). FPIA was injected as an intravenous bolus injection (range 342-368 MBq), and dynamic PET and MRI data were acquired simultaneously over 66 min.

Results: All patients tolerated the PET/MRI protocol. Three patients were reclassified following resection and histology. Tumour maximum standardised uptake value (SUVmax,60) increased in the order LGG (WHO grade 2) < HGG (WHO grade 3) < HGG (WHO grade 4). The net irreversible solute transfer, Ki, and influx rate constant, K1, were significantly higher in HGG (p < 0.05). Of the MRI variables studied, DCE-MRI-derived extravascular-and-extracellular volume fraction (ve) was high in tumours of WHO grade 4 compared with other grades (p < 0.05). SLC25A20 protein expression was higher in HGG compared with LGG.

Conclusion: Tumoural FPIA PET uptake is higher in HGG compared to LGG. This study supports further investigation of FPIA PET/MRI for brain tumour imaging in a larger patient population.

Clinical trial registration: Clinicaltrials.gov, NCT04097535.

Keywords: FPIA; Glioma; PET/MRI; Short-chain fatty acid; [18F]fluoropivalate.

PubMed Disclaimer

Conflict of interest statement

Financial interests: Eric O. Aboagye is inventor on a patent involving FPIA and has served in an advisor capacity to Radiopharm Theranostics Ltd and AstraZeneca. The authors declare no other relevant competing interests.

Figures

Fig. 1
Fig. 1
FPIA PET/MRI images in patients with grades II, III and IV gliomas. Axial PET and MRI images for grade II (PT01 and PT11), grade III (PT03, PT05, PT07) and grade IV (PT02, PT04, PT08, PT09, PT10) glioma patients including standardised uptake value for the last 5 time frames (SUV) from FPIA PET, T1 weighted MRI sequence, dynamic contrast-enhanced MRI (DCE)-contrast agent plasma/interstitium transfer rate constant (Ktrans), dynamic susceptibility contrast (DSC) MRI-cerebral blood volume (CBV), arterial spin labelling MRI-cerebral blood flow (CBF) and diffusion-weighted imaging MRI-apparent diffusion coefficient (ADC)
Fig. 2
Fig. 2
Image congruence. (A) Lesion mask outlined on the post-contrast T1 MRI image (red) and on the SUV40 and SUV30 (green). (B) Dynamic contrast-enhanced (DCE) MRI and SUV average tissue time activity curves in grade II (blue), grade III (red) and grade IV (green) for lesion or CWM
Fig. 3
Fig. 3
Blood to brain and tumour transit of FPIA. (A) Comparison of structural (longitudinal relaxation time on MRI-T1 post-contrast) and functional (FPIA PET SUVc) image sets from grade II (PT11), grade III (PT02) and grade IV (PT07) patients. (B) Spectrum of kinetic components evaluated in the lesion and CWM by spectral analysis. (C) Boxplots showing K1, Ki and VT parameters in grades II, III, IV and CWM
Fig. 4
Fig. 4
Assessment of the objective combination of PET and MRI variables for grade prediction. The least absolute shrinkage and selection operator (LASSO) was applied to extract a composite vector for tumour grade prediction from 24 (dynamic included) or 20 (static only) parameters determined by analysis of simultaneously acquired PET and MRI data. Five-fold cross-validation was performed to select lambda minimum to give the minimum cross-validated error for classifying LGG (grade II) versus HGG (grades III and IV) when (A) the PET variables were restricted to static data or (B) included dynamic PET data. The feature coefficients (b value) are indicated. (C) Boxplots showing ve parameter in grades II, III, IV and CWM

Comment in

Comment on

Similar articles

Cited by

References

    1. Lah TT, Novak M, Breznik B. Brain malignancies: glioblastoma and brain metastases. Semin Cancer Biol. 2020;60:262–273. doi: 10.1016/j.semcancer.2019.10.010. - DOI - PubMed
    1. Louis DN, Perry A, Wesseling P, Brat DJ, Cree IA, Figarella-Branger D, et al. The 2021 WHO classification of tumors of the central nervous system: a summary. Neuro Oncol. 2021;23:1231–1251. doi: 10.1093/neuonc/noab106. - DOI - PMC - PubMed
    1. Smits M. Imaging of oligodendroglioma. Brit J Radiol. 2016;89. doi:ARTN 20150857 10.1259/bjr.20150857. - PMC - PubMed
    1. Weller M, van den Bent M, Preusser M, Le Rhun E, Tonn JC, Minniti G, et al. EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood. Nat Rev Clin Oncol. 2021;18:170–186. doi: 10.1038/s41571-020-00447-z. - DOI - PMC - PubMed
    1. Henssen D, Leijten L, Meijer FJA, van der Kolk A, Arens AIJ, Ter Laan M, et al. Head-to-head comparison of PET and perfusion weighted MRI techniques to distinguish treatment related abnormalities from tumor progression in glioma. Cancers (Basel). 2023;15. doi:10.3390/cancers15092631. - PMC - PubMed

Substances

Associated data